NADAC Pricing Lookup
& Drug Pricing Database

Search weekly CMS NADAC prices by drug name or NDC, then analyze market, manufacturer, and class-level trends.

Weekly NADAC pricing brief
Week of November 18, 2026
Published NDCs
30,211
Price increases
15,052
Price decreases
13,763
Unchanged prices
1,296

NADAC Update: Biologic Price Relief Offsets Broad-Based Generic Increases

The November 18, 2026 NADAC release reflects a near-balanced market with 15,052 price increases against 13,763 decreases across 30,111 comparable NDCs, though dollar-weighted impact skews toward relief in high-cost specialty categories. The Interleukin-23 Antagonist class posted the largest aggregate price pressure at -$1.5M, driven primarily by risankizumab-rzaa, while AbbVie Inc. recorded the largest manufacturer-level decline (-$837.4K) across 64 products. Partially offsetting this, Risperidone saw a +3.5% average increase across 114 NDCs, contributing $677.1K in added cost, and broad-based Corticosteroid movement (1,102 drugs) remained modest despite its scale.

Key takeaways

  • Price activity was nearly even (15,052 increases vs. 13,763 decreases), indicating no dominant market-wide directional trend this week.
  • High-impact declines were concentrated in specialty and GLP-1 categories: Interleukin-23 Antagonist (-$1.5M), Opioid Antagonist (-$1.1M), and GLP-1 Receptor Agonist (-$922.3K) led dollar-weighted relief.
  • Generic breadth drove notable cost pressure, with Risperidone (+3.5%, 114 NDCs) and broad Corticosteroid movement (1,102 drugs) signaling sustained upward pressure outside specialty tiers.

What to watch

Naloxone Hydrochloride Pricing Shift

A -6.8% average move across 20 NDCs produced a -$986.8K impact, with Padagis Israel Pharmaceuticals products (including a -7.4% NDC-level decline) contributing significantly; payers should monitor formulary cost basis for opioid antagonists.

GLP-1 and Liraglutide Volatility

Liraglutide fell -8.0% across 12 NDCs (-$641.6K), part of a broader -$922.3K decline in the GLP-1 Receptor Agonist class; procurement teams should reassess contract pricing assumptions given continued downward momentum.

Interleukin-23 Antagonist Concentration Risk

Despite covering only 4 drugs, this class drove the largest weighted impact (-$1.5M), led by risankizumab-rzaa (-$739.6K across 2 NDCs) and AbbVie's broader -$837.4K swing; limited breadth means pricing shifts here can materially affect specialty drug budgets.

Market Signals

Latest 7-day price movements across drug markets, manufacturers, and therapeutic classes.

View All Trends

Drug Market Movers

See all Drug Markets

Manufacturer Activity

See all Manufacturers

Therapeutic Class Watch

See all Classes

Learn About NADAC Pricing

Explore guides and resources to understand drug pricing, access our comprehensive database, and track pharmaceutical market trends.